Testosterone Cypionate for HIV Wasting: Off-Label Evidence Summary

Is testosterone cypionate FDA-approved for HIV wasting?

The Depo-Testosterone label lists two uses: primary hypogonadism (congenital or acquired), meaning testicular failure from cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; and hypogonadotropic hypogonadism from gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma or radiation [1]. HIV-associated wasting is not among them. The same label says safety and efficacy in men with age-related hypogonadism have not been established, and Depo-Testosterone is labeled for males only [1]. FDA describes approved testosterone products the same way: for men who lack or have low testosterone along with an associated medical condition such as testicular failure or a hypothalamus or pituitary disorder, not for low testosterone without one [6]. FDA has asked for the age-related hypogonadism limitation to be removed, a request made in June 2026, but the Depo-Testosterone label checked still carries it [1][6].

So use in HIV wasting is off-label. When the low testosterone in a man with HIV fits one of the label's categories, the label's own indication applies; wasting as a diagnosis on its own is not an approved use.

How common is low testosterone in men with HIV?

In a 1988 study of 70 HIV-positive men, 20 of 40 men (50%) with AIDS were hypogonadal, and mean total testosterone was 401 +/- 30 ng/dL in AIDS and 292 +/- 70 ng/dL in AIDS-related complex, against 567 +/- 49 ng/dL in asymptomatic men and 608 +/- 121 ng/dL in normal men. Of the hypogonadal men, 18 of 24 (75%) had hypogonadotropic hypogonadism, and hypogonadism correlated with lymphocyte depletion and weight loss [7].

A 2000 study looked at 90 men who were below 90% of ideal body weight or had lost more than 10% of pre-illness weight; 71% were on combination antiretroviral therapy, and 21% of those on therapy had low free testosterone, with no correlation to weight, CD4 count or medication status [8]. A 1994 comparison of 66 HIV-positive patients found total and free testosterone significantly lower in the 14 men with wasting than in men without wasting at similar or higher CD4 counts [9].

What did the randomized trials find?

A 2002 systematic review and meta-analysis in Lancet Infectious Diseases pooled 8 placebo-controlled trials with 417 randomized patients; 6 of them reported lean body mass. The lean body mass difference between testosterone and placebo was 1.22 kg (95% CI 0.23 to 2.22) under a random-effects model and 0.51 kg (95% CI 0.09 to 0.93) under a fixed-effect model. In a post-hoc analysis of the 3 trials that used intramuscular testosterone, the difference was 3.34 kg. The total body weight difference was 1.04 kg (95% CI -0.01 to 2.10) random-effects and 0.63 kg (95% CI -0.01 to 1.28) fixed-effect, and the incidence of adverse effects was similar in both groups. The authors flagged the small numbers and heterogeneity of the populations as limitations [2].

A 1998 double-blind trial enrolled 51 HIV-positive men with wasting (weight below 90% of ideal body weight or more than 10% loss from baseline) and free testosterone below 42 pmol/L, randomizing them to testosterone enanthate 300 mg intramuscularly every 3 weeks or placebo for 6 months. Lean body mass rose 1.9 kg on testosterone versus 0.0 kg on placebo (P=0.041), fat-free mass 2.0 kg versus -0.6 kg (P=0.036), and muscle mass 2.4 kg versus -0.8 kg (P=0.005). Weight, fat mass, total body water and exercise capacity did not differ significantly, while men on testosterone reported feeling better (P=0.033) and improved quality of life (P=0.040) [3].

A 2000 JAMA trial randomized 61 HIV-infected men with testosterone below 349 ng/dL and at least 5% weight loss in the prior 6 months to placebo, testosterone enanthate 100 mg weekly, resistance exercise, or both, for 16 weeks; 49 men completed. Body weight rose 2.6 kg with testosterone alone (P<0.001), 2.2 kg with exercise alone, 0.7 kg with both, and fell 0.5 kg with placebo. Strength on leg press, leg curls, bench press and latissimus pulls improved 17% to 36%, with greater gains in the testosterone-plus-exercise and exercise-alone groups than in the placebo-alone group. Thigh muscle volume rose 40 cm3 with testosterone alone and 62 cm3 with exercise alone, against 5 cm3 with placebo [4].

A 2004 meta-analysis of 18 studies found recombinant human growth hormone, testosterone and anabolic steroids each increased lean body mass compared with placebo, with no statistically significant difference between the three in the size of that effect; the FDA-approved dose of growth hormone may have advantages for functional capacity and quality of life [10]. A 2014 systematic review of 36 studies concluded that testosterone is effective in HIV wasting for men who have hypogonadism, and that when hypogonadism is diagnosed alongside wasting, testosterone is a reasonable option [11].

Which testosterone ester did the trials use?

The two trials with reported regimens used testosterone enanthate, not cypionate [3][4]. The Depo-Testosterone label says testosterone esters in oil are absorbed slowly from the lipid phase, so cypionate can be given at intervals of two to four weeks, and gives a half-life after intramuscular injection of about eight days [1].

What dose does the label give?

For replacement in hypogonadal men, the Depo-Testosterone label gives 50 to 400 mg every 2 to 4 weeks by deep gluteal intramuscular injection, never intravenously, with the dose adjusted to response and adverse reactions. Before starting, the label calls for morning serum testosterone measured on at least two separate days, both below the normal range [1].

The wasting trials used 300 mg of enanthate every 3 weeks [3] and 100 mg of enanthate weekly [4].

HealthRX.com offers testosterone cypionate by prescription.

What are the main safety concerns?

Hematocrit

A 2022 network meta-analysis of 29 placebo-controlled randomized trials in 3,393 men found every testosterone formulation raised mean hematocrit versus placebo: intramuscular enanthate or cypionate by 4.0% (95% CI 2.9 to 5.1), oral testosterone undecanoate by 4.3%, gel by 3.0%, patch by 1.4%, and intramuscular testosterone undecanoate by 1.6% [5]. In a retrospective review of 178 hypogonadal men followed for 3 years, erythrocytosis (hematocrit above 50%) occurred in 66.7% of men on injectable testosterone, 35.1% on pellets and 12.8% on gels; the injection group was younger (mean 42.5 versus about 54 years) and had higher baseline hematocrit, and the study was not randomized [13]. The Depo-Testosterone label lists polycythemia as an adverse reaction and says to check hemoglobin and hematocrit periodically during long-term use [1].

Blood pressure and cardiovascular risk

The cypionate label carries no boxed warning. It warns that testosterone can increase blood pressure, which can increase cardiovascular risk over time, that blood pressure should be measured periodically, and that the product is not recommended in uncontrolled hypertension. The same label still contains the older paragraph saying long-term safety trials have not been conducted and that epidemiologic studies and randomized trials have been inconclusive for major adverse cardiovascular events, with some studies reporting an increased risk [1].

The largest cardiovascular trial, TRAVERSE, enrolled 5,246 men aged 45 to 80 with hypogonadism and existing or high risk of cardiovascular disease and tested daily 1.62% testosterone gel, not an injection. Major adverse cardiovascular events occurred in 7.0% on testosterone and 7.3% on placebo, hazard ratio 0.96 (95% CI 0.78 to 1.17), meeting noninferiority [14]. No outcome trial of that size exists for injectable testosterone [14]. Venous thromboembolism, including deep vein thrombosis and pulmonary embolism, has been reported with testosterone products, and the label says to stop treatment and evaluate if one is suspected [1].

Sperm production and fertility

Exogenous testosterone inhibits pituitary luteinizing hormone and, at large doses, follicle stimulating hormone, which suppresses sperm production; testicular atrophy, subfertility and infertility are reported in men who abuse anabolic steroids [1]. The Endocrine Society's 2018 guideline recommends against starting testosterone therapy in men planning fertility in the near term [15]. Recovery is common but variable: an integrated analysis of 30 studies in 1,549 healthy men on hormonal contraception found a median of 3.4 months to return to a sperm concentration of 20 million/mL, with 67% recovered by 6 months and 90% by 12 months [16]. Among 66 men with infertility after testosterone use who stopped and received high-dose hCG plus a selective estrogen receptor modulator, 46 (70%) reached a total motile count above 5 million within 12 months; 64.8% of azoospermic men did, against 91.7% of cryptozoospermic men, and older age and longer testosterone use predicted slower recovery [17].

Other label warnings

Edema, with or without congestive heart failure, can be serious in men with pre-existing cardiac, renal or hepatic disease. Gynecomastia may develop and occasionally persists. Hypercalcemia may occur in immobilized patients. Prolonged high doses of androgens, principally the 17-alpha-alkyl androgens, have been associated with hepatic adenomas, hepatocellular carcinoma and peliosis hepatis [1]. Contraindications are known hypersensitivity, breast carcinoma in men, known or suspected prostate carcinoma in men, pregnancy in women, and serious cardiac, hepatic or renal disease [1]. The Endocrine Society also recommends against starting testosterone in men with breast or prostate cancer, elevated hematocrit, untreated severe sleep apnea, uncontrolled heart failure, or a heart attack or stroke within 6 months [15].

What does the label say about drug interactions?

The drug interaction section of the Depo-Testosterone label includes the following. Androgens may increase sensitivity to oral anticoagulants, so the anticoagulant dose may need to be reduced, with INR and prothrombin time monitored more often when testosterone is started or stopped. Concurrent oxyphenbutazone and androgens may raise serum oxyphenbutazone levels. In diabetes, the metabolic effects of androgens may lower blood glucose and insulin requirements [1].

What monitoring do the label and guidelines call for?

The Depo-Testosterone label says hypogonadism should be confirmed with morning serum testosterone measured on at least two separate days, both below the normal range, that blood pressure be measured periodically, and that hemoglobin and hematocrit be checked periodically during long-term use [1]. The Endocrine Society's 2018 guideline recommends monitoring symptoms, serum testosterone, hematocrit and prostate cancer risk during the first year of therapy [15].

What remains uncertain?

The trials above measured lean body mass, strength, exercise capacity and quality of life; they were small, and they do not show whether testosterone improves survival or reduces hospitalization [2][3][4]. The two randomized trials described were published in 1998 and 2000. Low free testosterone was still present in 21% of men with HIV-related weight loss who were on combination therapy in a 2000 study, and the authors recommended screening such men and giving physiological androgen replacement if they are hypogonadal [8].